ALXN News and Press, Alexion Pharmaceuticals Inc. From 06/23/19

Noteworthy events during the week of June 23 - 29 for healthcare investors. More news on: Palatin Technologies, Inc., Calyxt, Inc., Acer Therapeutics Inc., Healthcare stocks news, , Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

The FDA accepts for priority review Alexion's (NASDAQ: ALXN ) supplemental Biologics License Application for Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. More news on: Alexion Pharmaceutica...

- FDA sets target action date of October 19, 2019 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS &#x...

- Physicians in Japan will soon be able to prescribe a treatment for PNH that requires fewer infusions, reducing the treatment burden for patients - - ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switchin...

- ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete C5 complement inhibition - - Nearly all surveyed patients preferred ULTOMIRIS over SOLIRIS ® (eculizumab) - Alexion Pharma...

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...

LOS ANGELES , May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico , Ph.D., initiates coverage on six stocks in the Healthcare and BioTech space. Initiations are on the following: Acer Therapeutics Inc. (ACER...